Patents by Inventor Timothy Colin Hancox
Timothy Colin Hancox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8697693Abstract: Thienopyrimidines of formula (Ia) or (Ib): wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.Type: GrantFiled: July 19, 2012Date of Patent: April 15, 2014Assignee: F. Hoffmann LaRoche AGInventors: Stewart James Baker, Paul John Goldsmith, Timothy Colin Hancox, Neil Anthony Pegg, Stephen Price, Stephen Joseph Shuttleworth, Sukhjit Sohai
-
Publication number: 20120283257Abstract: Thienopyrimidines of formula (Ia) or (Ib): wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.Type: ApplicationFiled: July 19, 2012Publication date: November 8, 2012Applicant: F. HOFFMANN-LA ROCHE AGInventors: Stewart James Baker, Paul John Goldsmith, Timothy Colin Hancox, Neil Anthony Pegg, Stephen Price, Stephen Joseph Shuttleworth, Sukhjit Sohal
-
Patent number: 8293735Abstract: Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110? isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: GrantFiled: October 27, 2008Date of Patent: October 23, 2012Assignee: F. Hoffmann-La Roche AGInventors: Timothy Colin Hancox, Neil Anthony Pegg, Alan John Nadin, Stephen Price
-
Patent number: 8252792Abstract: Thienopyrimidines of formula (Ia) or (Ib): wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.Type: GrantFiled: April 25, 2007Date of Patent: August 28, 2012Assignee: F. Hoffman-La Roche AGInventors: Stewart James Baker, Paul John Goldsmith, Timothy Colin Hancox, Neil Anthony Pegg, Stephen Price, Stephen Joseph Shuttleworth, Sukhjit Sohal
-
Patent number: 8168633Abstract: Thiazolopyrimidine compounds of formula I, where W represents a thiazole ring, selectively inhibit the p110 delta subtype of PI3 Kinase (PI3K), and are useful for treating diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: GrantFiled: January 7, 2011Date of Patent: May 1, 2012Assignee: Genentech, Inc.Inventors: Timothy Colin Hancox, Neil Anthony Pegg, Mandy Christine Beswick, Toby Jonathan Blench, Elsa Amandine Dechaux, Jahusz Jozef Kulagowski, Alan John Nadin, Stephen Price
-
Publication number: 20110230464Abstract: This invention provides a compound which is a purine of formula (Ia) or (Ib): and the pharmaceutically acceptable salts thereof that are inhibitors of PI3K and a selective for the p110? isoform, which is a class Ia PI3 kinase, over other class Ia PI3 kinases and over class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: ApplicationFiled: October 27, 2008Publication date: September 22, 2011Inventors: Paul Goldsmith, Timothy Colin Hancox, Nei Anthony Pegg, Janusz Josef Kulagowski, Alan John Nadin, Stephen Price
-
Publication number: 20110098270Abstract: Thiazolopyrimidine compounds of formula I, where W represents a thiazole ring, selectively inhibit the p110 delta subtype of PI3 Kinase (PI3K), and are useful for treating diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: ApplicationFiled: January 7, 2011Publication date: April 28, 2011Inventors: Timothy Colin Hancox, Neil Anthony Pegg, Mandy Christine Beswick, Toby Jonathan Blench, Elsa Amandine Dechaux, Jahusz Jozef Kulagowski, Alan John Nadin, Stephen Price
-
Patent number: 7893060Abstract: Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; R1 and R2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; R3 is H or C1-C6 alkyl; and R4 is an indole group which is unsubstituted or substituted; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110? isoform, which is a class Ia PD kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: GrantFiled: June 12, 2008Date of Patent: February 22, 2011Assignee: F. Hoffmann-La Roche AGInventors: Timothy Colin Hancox, Neil Anthony Pegg, Mandy Christine Beswick, Toby Jonathan Blench, Elsa Amandine Dechaux, Janusz Jozef Kulagowski, Alan John Nadin, Stephen Price
-
Publication number: 20110021496Abstract: Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110? isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: ApplicationFiled: October 27, 2008Publication date: January 27, 2011Applicant: F. HOFFMANN-LA ROCHE AGInventors: Timothy Colin Hancox, Neil Anthony Pegg, Alan John Nadin, Stephen Price
-
Publication number: 20100256143Abstract: The invention provides a pyrimidine compound of formula (I): wherein R1 and R2 have any of the values defined herein; or a pharmaceutically acceptable salt thereof. The compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: ApplicationFiled: April 14, 2008Publication date: October 7, 2010Inventors: Stewart James Baker, Paul John Goldsmith, Timothy Colin Hancox, Neil Anthony Pegg, Stephen Joseph Shuttleworth, Elsa Amandine Dechaux, Sussie Lerche Krintel, Stephen Price, Jonathan Martin Large, Edward McDonald
-
Publication number: 20100210646Abstract: The invention provides a pyrimidine compound of formula (I): wherein R1 and R2 have any of the values defined herein; or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: ApplicationFiled: April 14, 2008Publication date: August 19, 2010Applicants: F. Hoffmann-La Roche AG, The Institute of Cancer Research: Royal Cancer Hos pitalInventors: Paul John Goldsmith, Timothy Colin Hancox, Neil Anthony Pegg, Stephen Joseph Shuttleworth, Jonathan Martin Large, Edward McDonald
-
Publication number: 20100190769Abstract: Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; R1 and R2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; R is H or C1-C6 alkyl; and R is an indole group which is unsubstituted or substituted; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110? isoform, which is a class Ia PD kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: ApplicationFiled: June 12, 2008Publication date: July 29, 2010Inventors: Timothy Colin Hancox, Neil Anthony Pegg, Mandy Christine Beswick, Toby Jonathan Blench, Elsa Amandine Dechaux, Janusz Jozef Kulagowski, Alan John Nadin, Stephen Price
-
Publication number: 20100130496Abstract: The invention provides a pyrimidine compound of formula (I): wherein R1, R2, and Y have any of the values defined herein; or a pharmaceutically acceptable salt thereof. The compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: ApplicationFiled: April 14, 2008Publication date: May 27, 2010Applicants: F. Hoffmann-La Roche AG, The Institute of Cancer Research: Royal Cancer HospitalInventors: Paul John Goldsmith, Timothy Colin Hancox, Neil Anthony Pegg, Stephen Joseph Shuttleworth, Elsa Amandine Dechaux, Stephen Price, Jonathan Martin Large, Edward McDonald
-
Publication number: 20100016306Abstract: Thienopyrimidines of formula (Ia) or (Ib): wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.Type: ApplicationFiled: April 25, 2007Publication date: January 21, 2010Applicant: F. Hoffmann-La Roche AGInventors: Stewart James Baker, Paul John Goldsmith, Timothy Colin Hancox, Neil Anthony Pegg, Stephen Price, Stephen Joseph Shuttleworth, Sukhjit Sohal